Share buyback programs are often seen as a sign of a company's confidence in its own stock. By reducing the number of shares available in the market, it can create upward pressure on the stock price. Therefore, Dexcom's announcement is likely to be viewed positively by investors and could lead to an increase in the company's stock price.